Themis Biosciences Signs an Exclusive License Agreement with Max-Planck-Innovation for Oncolytic Virotherapies
Shots:
- Themis to get global rights to develop- manufacture and commercialize therapies based on an oncolytic measles virus platform- collaborately developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry
- The agreement focus on expanding immunomodulation portfolio for developing multiple immuno-oncology therapeutics
- The licensed technology is based on the viral genome sequence of the measles vaccine strain used to immunize globally and can also be used for killing tumor cells
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com